博暉創新(300318.SZ):控股子公司產品產業化項目獲得政府補助550萬元
格隆匯4月1日丨博暉創新(300318.SZ)公佈,公司於近日收到控股子公司河北大安製藥有限公司(“河北大安”)的通知,獲悉其收到石家莊市發展和改革委員會轉發《河北省發展和改革委員會關於2020年第一批省高技術產業化項目的覆函》(冀發改高技【2020】297號)的通知,河北大安產品產業化項目已被列為2020年第一批省高技術產業化項目的支持範圍。
項目名稱:河北大安製藥有限公司人凝血酶原複合物等凝血因子類產品產業化項目;主要建設內容:採用“一種用於純化凝血酶原複合物的工藝”技術,擁有自主知識產權。改造現有生產車間建築面積864.5㎡,利用原有設備16台(套),購置灌裝加塞機、凍幹機等52台(套),形成年產人凝血酶原複合物1300瓶的試生產能力。建設地點位於石家莊市鹿泉區,建設期為2018年-2020年。總投資:3900萬元;安排補助:550萬元;管理部門:石家莊市發展改革委。
補助資金主要用於項目實施所需的技術研發、產業化和應用示範過程中的設備購置和應用推廣、公共服務平台建設及必要的配套基礎設施建設等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.